Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Net loss $ (40,494) $ (58,092) $ (15,625)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 481 342 228
Stock-based compensation 8,793 2,211 439
Stock-based compensation to service providers 354 115 52
Revaluation of warrants and accretion (8,122) 6,599 1,106
Revaluation of convertible loan 17,866
Change in operating assets and liabilities:      
Increase in trade receivable (2,015) (50) (137)
Decrease (increase) in prepaid expenses and other receivables 1,219 (2,228) (371)
Operating lease ROU assets and liabilities, net (84)
Increase (decrease) in trade payables (769) 458 (1,063)
Increase (decrease) in employees and payroll accruals (234) 1,557 367
Increase (decrease) in deferred revenue (375) 445 75
Increase (decrease) in accrued expenses and other payables 884 4,361 (356)
Net cash used in operating activities (40,362) (26,416) (15,285)
Cash flows from investing activities:      
Change in bank deposits (400) 100 9,860
Purchase of property and equipment (918) (784) (156)
Net cash provided by (used in) investing activities (1,318) (684) 9,704
Cash flows from financing activities:      
Proceeds from short-term loan 4,715
Repayment of long-term loan (2,639) (1,585)
Proceeds from issuance of redeemable convertible preferred shares and warrants for the purchase of Series B-2 redeemable convertible preferred shares 1,190
Proceeds from recapitalization and PIPE offering, net of issuance costs 98,587
Repayment of short-term loan (5,218)    
Proceeds from exercise of warrants 12,859 256
Proceeds from exercise of options 277 223 30
Proceeds from convertible loan 11,337 1,641
Net cash provided by (used in) financing activities (4,941) 125,082 1,532
Effect of exchange rate fluctuations on cash and cash equivalent (1,189)
Increase (decrease) in cash, cash equivalents and restricted cash (45,432) 97,982 (4,049)
Cash, cash equivalents and restricted cash at the beginning of the year 100,936 2,954 7,003
Cash, cash equivalents and restricted cash at the end of the year 54,315 100,936 2,954
Supplemental non-cash disclosure:      
Exercise of warrants into convertible preferred shares 4,389 85
Issuance of private warrants 6,598
Conversion of convertible loan into ordinary shares upon the recapitalization 30,844
Conversion of preferred shares into ordinary shares upon the recapitalization 63,467
Purchase of property and equipment $ 7 $ 340